-

Crescita Announces Exclusive Canadian Distribution Agreement with Obagi Cosmeceuticals LLC

LAVAL, Québec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (“Crescita”), a growth-oriented, innovation-driven Canadian commercial dermatology company, is pleased to announce that it has entered into a distribution agreement with Obagi Cosmeceuticals LLC (“Obagi”) for the exclusive rights to promote, distribute and sell the Obagi Medical® product line in Canada.

The Obagi Medical line provides transformational skincare products formulated to minimize signs of aging, address dark spots, hyperpigmentation, fine lines and wrinkles and to protect and enhance skin tone and texture. Crescita will promote and sell the products nationwide through its existing network.

Serge Verreault, President and Chief Executive Officer of Crescita, commented, “We are pleased to welcome Obagi as our newest distribution partner. We believe this partnership is a logical next step in the expansion of our product portfolio in the growing medical aesthetics market and are excited about bringing these premium, innovative and effective products back to Canadian consumers.”

Jaime Castle, President & Chief Executive Officer of Obagi Cosmeceuticals, LLC, commented, “We are thrilled to initiate the relaunch of the Obagi® brand to Canadian consumers alongside our partner, Crescita Therapeutics. Obagi’s innovative products & global expansion strategy are perfectly matched with Crescita’s proven reputation within the Canadian aesthetic space. We look forward to a long & productive partnership together.”

About Crescita Therapeutics Inc.

Crescita (TSX: CTX and OTC US: CRRTF) is a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house R&D and manufacturing capabilities. The Company offers a portfolio of high-quality, science-based non-prescription skincare products and early to commercial stage prescription products. In addition, we own multiple proprietary transdermal delivery platforms that support the development of patented formulations that facilitate the delivery of active ingredients into or through the skin.

About Obagi Cosmeceuticals, LLC.

Obagi is an advanced global skin care company dedicated to providing advanced, clinically proven skin care treatments for all skin types. With a 30-year legacy and commitment to diversity and inclusion in all aspects of its business – from its corporate culture to product development – Obagi has pioneered a number of skin care advances, including being the first skin care brand to design its clinical research covering all six skin types across the Fitzpatrick skin spectrum. Through an extensive network of distributors, partners and physician offices in over 90 countries around the world, the company provides more than 100 Obagi products to brighten, nourish, protect, and enhance skin tone and texture.

Contacts

Crescita Therapeutics
Investor Relations
Linda Kisa, CPA, CA
Email: lkisa@crescitatx.com

Crescita Therapeutics

TSX:CTX

Release Versions

Contacts

Crescita Therapeutics
Investor Relations
Linda Kisa, CPA, CA
Email: lkisa@crescitatx.com

More News From Crescita Therapeutics

Crescita Therapeutics Inc. Announces Closing of Arrangement

LAVAL, Québec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”) is pleased to announce the closing of the previously announced plan of arrangement (the “Arrangement”) with ClinActiv Holdings Inc. (“ClinActiv”) and its wholly-owned subsidiary (the “Purchaser”), pursuant to which the Purchaser acquired all the issued and outstanding common shares of the Company (the “Shares”) in exchange for cash consideration of $0.80 per Share (the “Consider...

Crescita Therapeutics Inc. Announces Final Consideration Payable to Shareholders Pursuant to Arrangement with ClinActiv

LAVAL, Québec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”) is pleased to announce that holders of the issued and outstanding common shares (the “Shares”) of the Company (each a “Shareholder”) will be entitled to receive $0.80 per Share (subject to any applicable withholdings) (the “Consideration”) under its previously announced plan of arrangement (the “Arrangement”) with ClinActiv Holdings Inc. (“ClinActiv”) and its wholly-owned subsid...

Crescita Therapeutics Inc. Obtains Final Order Approving Plan of Arrangement

LAVAL, Québec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”) is pleased to announce that it has obtained a final court order from the Ontario Superior Court of Justice (Commercial List) approving its previously announced plan of arrangement (the “Arrangement”) with ClinActiv Holdings Inc. (“ClinActiv”) and its wholly-owned subsidiary (the “Purchaser”), pursuant to which the Purchaser will acquire all of the issued and outstanding common s...
Back to Newsroom